Patents Represented by Attorney, Agent or Law Firm Stuart Watt
  • ACPL polypeptides
    Patent number: 6693171
    Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: February 17, 2004
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Teresa L. Born
  • ACPL antibodies
    Patent number: 6692740
    Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: February 17, 2004
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Teresa L. Born
  • CD45 disrupted nucleic acid
    Patent number: 6664107
    Abstract: A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: December 16, 2003
    Assignee: Ontario Cancer Institute, University Health Network
    Inventors: Tak Wah Mak, Kenji Kishihara
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Patent number: 6652854
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&agr; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&agr; inhibitors.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: November 25, 2003
    Assignee: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Mary K. Kennedy
  • ULBP DNA and polypeptides
    Patent number: 6653447
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: November 25, 2003
    Assignee: Immunex Corporation
    Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
  • Receptor that binds trail
    Patent number: 6642358
    Abstract: A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors containing the DNA sequences, and host cells transformed with such recombinant expression vectors. Antibodies that are immunoreactive with TRAIL-R are also provided.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: November 4, 2003
    Assignee: Immunex Corporation
    Inventors: Charles Rauch, Henning Walczak